As a specialist formulation development company, we recognise that new compounds, especially those with poor aqueous solubilities, have a better chance of succeeding if properly formulated for animal safety and efficacy testing.
In the perpetual haste to complete various steps of a drug development plan, formulations of new drugs may not be given sufficient consideration for initial preclinical evaluation, resulting in the development of suboptimal or unstable dosing vehicles and ultimately poor drug absorption. Furthermore, the constraints of business mean that formulators often have less time, money and resources to spend developing each compound.
In order to facilitate the development of poorly soluble compounds, we have implemented the SOLENT™ Array, a high-throughput, semi-automated platform designed to rapidly screen for and identify enabling formulation strategies to support preclinical efficacy and safety investigations.
SOLENT™ Array can be incorporated as part of any drug discovery program and is currently used by numerous pharmaceutical, biotechnology and academic laboratories around the world.
Benefits of the SOLENT™ screening platform include: